Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

LYBALVI 15-10 MG TABLET

olanzapine and samidorphan L-malate
$55.0894per EA

Strength

15; 10 mg/1; mg/1

Manufacturer

Alkermes, Inc.

NDC

65757065342

Classification

Brand

Dosage Form

TABLET, FILM COATED

Route

ORAL

Last Updated

1/1/2026

Active Ingredients

OLANZAPINE; SAMIDORPHAN L-MALATE

Approval Type

New Drug (NDA)

FDA Application

NDA213378

On Market Since

9/20/2021

Pharmacological Classes

Atypical Antipsychotic
Opioid Antagonist
Opioid Antagonists

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

+5.0%

1Y

+4.9%

3Y

+17.8%

5Y

N/A

All

+24.3%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

SEROQUEL 25 MG TABLET
Brand
00310027510•AstraZeneca Pharmaceuticals LP
$3.7050
per EA
RISPERDAL 0.5 MG TABLET
Brand
50458030201•Janssen Pharmaceuticals Inc.
$4.3928
per EA
RISPERDAL 0.5 MG TABLET
Brand
50458030206•Janssen Pharmaceuticals Inc.
$4.3928
per EA
RISPERDAL 1 MG TABLET
Brand
50458030001•Janssen Pharmaceuticals Inc.
$4.6958
per EA
RISPERDAL 1 MG TABLET
Brand
50458030006•Janssen Pharmaceuticals Inc.
$4.6958
per EA
SUBOXONE 2 MG-0.5 MG SL FILM
Brand
12496120203•Indivior Inc.
$4.7853
per EA
CONTRAVE ER 8-90 MG TABLET
Brand
51267089099•Nalpropion Pharmaceuticals LLC
$4.9810
per EA
RISPERDAL 1 MG/ML SOLUTION
Brand
50458030503•Janssen Pharmaceuticals Inc.
$5.2507
per ML
ZUBSOLV 0.7-0.18 MG TABLET SL
Brand
54123090730•Orexo US, Inc.
$5.2599
per EA
ZUBSOLV 1.4-0.36 MG TABLET SL
Brand
54123091430•Orexo US, Inc.
$5.2767
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy